Developing new drugs to treat serious disorders of the central nervous system

About

Autifony Therapeutics aims to develop new drugs to treat serious disorders of the central nervous system using pioneering science.

Science

Scientific publications can be found here as well as information on Voltage-gated ion channels as therapeutics targets and Kv3 ion channels.

Pipeline

Clinical stage programmes for schizophrenia and Fragile X, and earlier stage programmes focused on Hearing disorders and Alzheimer’s Disease.

Tweets

AutifonyLtd @AutifonyLtd
Autifony Therapeutic  @AutifonyLtd
RT @BIODeutschland:Boehringer Ingelheim & Autifony Therapeutics collaborate on a novel therapeutic approach to a range of CNS disorder… https://t.co/sIz3B7CkOe 
Dec 18 reply retweet favorite 5 months ago
Autifony Therapeutic  @AutifonyLtd
We have a very exciting announcement today! https://t.co/ofHB6LG3ZL 
Dec 18 reply retweet favorite 5 months ago
Autifony Therapeutic  @AutifonyLtd
Our new website is now live #excitingtimes 
Dec 15 reply retweet favorite 5 months ago

News & Events

18th December 2017

Autifony Therapeutics and Boehringer Ingelheim collaborate on a novel therapeutic approach to a range of CNS disorders

Find Out More
10th July 2017

Autifony Therapeutics receives Orphan Drug Designation for AUT00206 for Fragile X Syndrome

Find Out More

Tweets

AutifonyLtd @AutifonyLtd
Autifony Therapeutic  @AutifonyLtd
RT @BIODeutschland:Boehringer Ingelheim & Autifony Therapeutics collaborate on a novel therapeutic approach to a range of CNS disorder… https://t.co/sIz3B7CkOe 
Dec 18 reply retweet favorite 5 months ago
Autifony Therapeutic  @AutifonyLtd
We have a very exciting announcement today! https://t.co/ofHB6LG3ZL 
Dec 18 reply retweet favorite 5 months ago
Autifony Therapeutic  @AutifonyLtd
Our new website is now live #excitingtimes 
Dec 15 reply retweet favorite 5 months ago

Back to Top
Responsive Menu Pro Image Responsive Menu Clicked Image